Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO

被引:17
作者
Artenie, Adelina [1 ,2 ]
Luhmann, Niklas [3 ]
Lim, Aaron G. [1 ,2 ]
Fraser, Hannah [1 ,2 ]
Ward, Zoe [1 ,2 ]
Stone, Jack [1 ,2 ]
MacGregor, Louis [1 ,2 ]
Walker, Josephine G. [1 ,2 ]
Trickey, Adam [1 ,2 ]
Marquez, Lara K. [4 ]
Abu-Raddad, Laith J. [5 ]
Ayoub, Houssein H. [6 ]
Walsh, Nick [3 ]
Hickman, Matthew [1 ,2 ]
Martin, Natasha K. [4 ]
Easterbrook, Philippa [3 ]
Vickerman, Peter [1 ,2 ]
机构
[1] Univ Bristol, Dept Populat Hlth Sci, Bristol, Avon, England
[2] Univ Bristol, Natl Inst Hlth Res Hlth Protect Res Unit Behav Sc, Bristol, Avon, England
[3] WHO, Global HIV Hepatitis & Sexually Transmitted Infec, Geneva, Switzerland
[4] Univ Calif San Diego, Div Infect Dis & Global Publ Hlth, La Jolla, CA 92093 USA
[5] Cornell Univ, Weill Cornell Med Qatar, Doha, Qatar
[6] Qatar Univ, Dept Math Stat & Phys, Doha, Qatar
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
INJECT DRUGS; VIRAL-HEPATITIS; ANTIBODY AVIDITY; SYRINGE PROGRAMS; UNITED-STATES; HCV INCIDENCE; PREVALENCE; HIV; RISK; TRANSMISSION;
D O I
10.1016/S2468-1253(21)00311-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
One of the main goals of the 2016 Global Health Sector Strategy on viral hepatitis is the elimination of hepatitis C virus (HCV) as a public health problem by 2030, defined as an 80% reduction in incidence and 65% reduction in mortality relative to 2015. Although monitoring HCV incidence is key to validating HCV elimination, use of the gold-standard method, which involves prospective HCV retesting of people at risk, can be prohibitively resource-intensive. Additionally, few countries collected quality data in 2015 to enable an 80% decrease by 2030 to be calculated. Here, we first review different methods of monitoring HCV incidence and discuss their resource implications and applicability to various populations. Second, using mathematical models developed for various global settings, we assess whether trends in HCV chronic prevalence or HCV antibody prevalence or scale-up levels for HCV testing, treatment, and preventative interventions can be used as reliable alternative indicators to validate the HCV incidence target. Third, we discuss the advantages and disadvantages of an absolute HCV incidence target and suggest a suitable threshold. Finally, we propose three options that countries can use to validate the HCV incidence target, depending on the available surveillance infrastructure.
引用
收藏
页码:353 / 366
页数:14
相关论文
共 78 条
[1]   Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study [J].
Akiyama, Matthew J. ;
Cleland, Charles M. ;
Lizcano, John A. ;
Cherutich, Peter ;
Kurth, Ann E. .
LANCET INFECTIOUS DISEASES, 2019, 19 (11) :1255-1263
[2]  
[Anonymous], 2016, HEP C DRUG US EUR EP
[3]  
[Anonymous], 2016, Kisarawe Activity Report
[4]  
Arum C, 2021, LANCET PUBLIC HEALTH, V6, pE309, DOI [10.1016/S2468-2667(21)00013, 10.1016/S2468-2667(21)00013-X]
[5]   Excellence in viral hepatitis elimination - Lessons from Georgia [J].
Averhoff, Francisco ;
Lazarus, Jeffrey V. ;
Sergeenko, David ;
Colombo, Massimo ;
Gamkrelidze, Amiran ;
Tsertsvadze, Tengiz ;
Butsashvili, Maia ;
Metreveli, David ;
Sharvadze, Lali ;
Hellard, Margaret ;
Gnes, Stefano ;
Gabunia, Tamar ;
Nasrullah, Muazzam .
JOURNAL OF HEPATOLOGY, 2019, 71 (04) :645-647
[6]   Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention [J].
Ayoub, H. H. ;
Abu-Raddad, L. J. .
JOURNAL OF VIRAL HEPATITIS, 2017, 24 (06) :486-495
[7]   Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections [J].
Ayoub, Houssein H. ;
Abu-Raddad, Laith J. .
BMJ OPEN, 2019, 9 (05)
[8]   Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy [J].
Boerekamps, Anne ;
van den Berk, Guido E. ;
Lauw, Fanny N. ;
Leyten, Eliane M. ;
van Kasteren, Marjo E. ;
van Eeden, Arne ;
Posthouwer, Dirk ;
Claassen, Mark A. ;
Dofferhoff, Anton S. ;
Verhagen, Dominique W. M. ;
Bierman, Wouter F. ;
Lettinga, Kamilla D. ;
Kroon, Frank P. ;
Delsing, Corine E. ;
Groeneveld, Paul H. ;
Soetekouw, Robert ;
Peters, Edgar J. ;
Hullegie, Sebastiaan J. ;
Popping, Stephanie ;
van de Vijver, David A. M. C. ;
Boucher, Charles A. ;
Arends, Joop E. ;
Rijnders, Bart J. .
CLINICAL INFECTIOUS DISEASES, 2018, 66 (09) :1360-1365
[9]   Antibody avidity-based approach to estimate population-level incidence of hepatitis C [J].
Boon, Denali ;
Bruce, Veronica ;
Patel, Eshan U. ;
Quinn, Jeffrey ;
Srikrishnan, Aylur K. ;
Shanmugam, Saravanan ;
Iqbal, Syed ;
Balakrishnan, Pachamuthu ;
Sievers, Matthew ;
Kirk, Gregory D. ;
Thomas, David L. ;
Quinn, Thomas C. ;
Cox, Andrea L. ;
Page, Kimberly A. ;
Solomon, Sunil S. ;
Mehta, Shruti H. ;
Laeyendecker, Oliver .
JOURNAL OF HEPATOLOGY, 2020, 73 (02) :294-302
[10]   Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation [J].
Busch, Michael P. ;
Pilcher, Christopher D. ;
Mastro, Timothy D. ;
Kaldor, John ;
Vercauteren, Gaby ;
Rodriguez, William ;
Rousseau, Christine ;
Rehle, Thomas M. ;
Welte, Alex ;
Averill, Megan D. ;
Calleja, Jesus M. Garcia .
AIDS, 2010, 24 (18) :2763-2771